- Home
- MGNX vs TYGO Comparison
MGNX vs TYGO Comparison
Compare MGNX & TYGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- TYGO
- Stock Information
- Founded
- MGNX 2000
- TYGO 2007
- Country
- MGNX United States
- TYGO United States
- Employees
- MGNX N/A
- TYGO N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- TYGO Semiconductors
- Sector
- MGNX Health Care
- TYGO Technology
- Exchange
- MGNX Nasdaq
- TYGO Nasdaq
- Market Cap
- MGNX 99.7M
- TYGO 116.0M
- IPO Year
- MGNX 2013
- TYGO N/A
- Fundamental
- Price
- MGNX $1.86
- TYGO $2.09
- Analyst Decision
- MGNX Hold
- TYGO Strong Buy
- Analyst Count
- MGNX 6
- TYGO 1
- Target Price
- MGNX $3.20
- TYGO $6.00
- AVG Volume (30 Days)
- MGNX 726.3K
- TYGO 572.0K
- Earning Date
- MGNX 11-04-2025
- TYGO 10-28-2025
- Dividend Yield
- MGNX N/A
- TYGO N/A
- EPS Growth
- MGNX N/A
- TYGO N/A
- EPS
- MGNX N/A
- TYGO N/A
- Revenue
- MGNX $165,495,000.00
- TYGO $74,405,000.00
- Revenue This Year
- MGNX N/A
- TYGO $94.76
- Revenue Next Year
- MGNX N/A
- TYGO $23.23
- P/E Ratio
- MGNX N/A
- TYGO N/A
- Revenue Growth
- MGNX 303.47
- TYGO 52.31
- 52 Week Low
- MGNX $0.99
- TYGO $0.58
- 52 Week High
- MGNX $5.10
- TYGO $2.95
- Technical
- Relative Strength Index (RSI)
- MGNX 55.15
- TYGO 42.93
- Support Level
- MGNX $1.82
- TYGO $2.30
- Resistance Level
- MGNX $2.15
- TYGO $2.53
- Average True Range (ATR)
- MGNX 0.13
- TYGO 0.22
- MACD
- MGNX 0.01
- TYGO -0.05
- Stochastic Oscillator
- MGNX 49.15
- TYGO 10.22
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.